Search

Your search keyword '"Sollberg, Stephan"' showing total 2 results
Start Over Author "Sollberg, Stephan" Database MEDLINE
2 results on '"Sollberg, Stephan"'

2. Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site.

Author

Lauer G, Sollberg S, Cole M, Krieg T, and Eming SA

Subjects
Animals, COS Cells, Cell Division, Cells, Cultured, Dose-Response Relationship, Drug, Endothelial Growth Factors chemistry, Endothelial Growth Factors pharmacology, Humans, Intercellular Signaling Peptides and Proteins chemistry, Intercellular Signaling Peptides and Proteins pharmacology, Kinetics, Lymphokines chemistry, Lymphokines pharmacology, Mutagenesis, Site-Directed, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors, Wound Healing, Endothelial Growth Factors genetics, Endothelial Growth Factors metabolism, Fibrinolysin metabolism, Intercellular Signaling Peptides and Proteins genetics, Intercellular Signaling Peptides and Proteins metabolism, Lymphokines genetics, Lymphokines metabolism
Abstract

Vascular endothelial growth factor (VEGF) is a potent angiogenic mediator in tissue repair. In non-healing human wounds plasmin cleaves and inactivates VEGF165. In the present study, we generated recombinant VEGF165 mutants resistant to plasmin proteolysis. Substitution of Arg110 with Ala110 or Gln110, and Ala111 with Pro111 yielded plasmin-resistant and biologically active VEGF165 mutants. In addition, substitution of Ala111 with Pro111 resulted in a substantial degree of stabilization when incubated in wound fluid obtained from non-healing wounds. These results suggest that the plasmin cleavage site Arg110/Ala111 and the carboxyl-terminal domain play an important role in the mitogenic activity of VEGF165.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results